UNSPSC 51144602: Diethylpropion hydrochloride

This classification denotes a cns stimulant and anorexiant with the molecular formula C13H19NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19V2PL39NG, chemically known as 1-propanone, 2-(diethylamino)-1-phenyl- but more generally known as amfepramone hydrochloride, which bears US NIH Compound Identifier 7029. European Medicines Agency schedules Amfepramone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00434MIG.

As of Q4 2014, DIETHYLPROPION HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Diethylpropion hydrochloride bears US NLM identifiers UMLS ID C0723644 and NCI Concept Code C47486. SMILES: O=C(C(N(CC)CC)C)C1CCCCC1.

UNSPSC 51144602 Diethylpropion hydrochloride is a Commodity code nominally naming a controlled-substance appetite suppressant, but recent state and local procurement activity under this code does not consistently reflect that specific pharmaceutical. Instead, state and local governments are using the code to solicit broader pharmaceutical procurement — primarily generic multi-source drugs, over-the-counter products, naloxone, and direct-to-manufacturer prescription programs that support community health, pharmacy benefit management, and emergency response initiatives. The issuing bodies include state health and human services departments, county public-health agencies, and cooperative purchasing alliances representing multiple states and municipalities. Work solicited ranges from annual purchases of naloxone and drug deactivation systems for community distribution through cooperative pharmaceutical supply contracts serving dozens of jurisdictions simultaneously.

Activity under this code spans Florida, Texas, and Minnesota, with the most recent opportunities posted between April and June 2026. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response deadline July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring how state agencies and self-insured plans might bypass traditional pharmacy benefit managers and wholesalers. Most significantly, the Minnesota Department of Administration's Office of State Procurement issued an RFP through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) in January 2026 for generic multi-source pharmaceuticals and OTC products with response deadline March 26, 2026, requiring vendors to work through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and serve participating jurisdictions in Minnesota and Oregon. The mismatch between the code's nominal scope and actual recent procurement suggests caution — vendors should verify code alignment in specific opportunities before investing in pursuit.